Press Releases
  Date Title View
Posted: Jan 12, 2006
Rockville, MD, February 21, 2006 - Supernus Pharmaceuticals, Inc., announces the closing of a second round of financing raising an additional $17.5 million. This completes the Series A funding for a total of $45 million. The company announced last month the closing of the first round of financing and the acquisition of substantially all the as...
Posted: Feb 21, 2006
Posted: Jun 13, 2006
Posted: Jun 26, 2006
August 6, 2007 - Indevus Pharmaceuticals, Inc (Nasdaq: IDEV), a Supernus Pharmaceuticals Partner, today announced that Sanctura® XR (trospium chloride extended release capsules) has been approved by the U.S. Food and Drug Administration (FDA). CONTACT: Russell "Rip" Wilson Chief Financial Officer Supernus Pharmaceu...
Posted: Aug 6, 2007
September 19, 2007 - Indevus Pharmaceuticals, Inc (Nasdaq: IDEV), a Supernus Pharmaceuticals Partner, today announced that Allergan, Inc. (NYSE: AGN), through its acquisition of Esprit Pharma, has obtained the United States rights to Sanctura® and Sanctura® XR. CONTACT: Russell "Rip" Wilson Chief Financial Officer Supe...
Posted: Sep 19, 2007
Rockville, MD., December 17, 2008 — Supernus Pharmaceuticals, Inc. today announced the initiation of the pivotal Phase III clinical trial for its lead product SPN-804. The trial is a randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of SPN-804 for the adjunctive treatment o...
Posted: Dec 17, 2008
Rockville, MD., January 30, 2009 — Supernus Pharmaceuticals Inc. today announced the initiation of a Phase IIa U.S. clinical trial of its product candidate SPN810 in the treatment of serious conduct problems in the setting of ADHD. The trial is a proof-of-concept, open-label study with pediatric subjects randomiz...
Posted: Jan 30, 2009
Rockville, MD, January 27, 2010 – Supernus Pharmaceuticals Inc., today announced that its Phase IIa U.S. clinical trial for SPN 810 in children with ADHD and persistent serious conduct problems met the primary endpoints of safety and tolerability, as well as showed statistically significant reduction versus basel...
Posted: Jan 27, 2010
Rockville, MD, July 13, 2010 – Supernus Pharmaceuticals Inc. today announced the initiation of a Phase IIa U.S. clinical trial of its product candidate SPN812 for the treatment of ADHD in adults. The trial is a proof-of-concept, randomized, double-blind, placebo-controlled study in healthy adults aged 18 to 64, i...
Posted: Jul 13, 2010
1
...
NextLast
= add release to Briefcase